These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 18828070)

  • 1. British Association for Psychopharmacology--2008 Summer Meeting.
    Jenkins TA
    IDrugs; 2008 Oct; 11(10):720-3. PubMed ID: 18828070
    [No Abstract]   [Full Text] [Related]  

  • 2. Atypical neuroleptics in children and adolescents.
    Scahill L; Lynch KA
    J Child Adolesc Psychiatr Nurs; 1998; 11(1):38-43. PubMed ID: 9611543
    [No Abstract]   [Full Text] [Related]  

  • 3. Current and novel approaches to the drug treatment of schizophrenia.
    Rowley M; Bristow LJ; Hutson PH
    J Med Chem; 2001 Feb; 44(4):477-501. PubMed ID: 11170639
    [No Abstract]   [Full Text] [Related]  

  • 4. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.
    Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY
    Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schizophrenia: from dopamine to glutamate and back.
    Carlsson ML; Carlsson A; Nilsson M
    Curr Med Chem; 2004 Feb; 11(3):267-77. PubMed ID: 14965231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology.
    Paz RD; Tardito S; Atzori M; Tseng KY
    Eur Neuropsychopharmacol; 2008 Nov; 18(11):773-86. PubMed ID: 18650071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The roadmap for antipsychotic psychopharmacology: an overview.
    Roadmap Editorial Board
    J Clin Psychiatry; 2007 Nov; 68(11):1799-806. PubMed ID: 18052575
    [No Abstract]   [Full Text] [Related]  

  • 8. Schizophrenia clues from monkeys.
    Pennisi E
    Science; 1997 Aug; 277(5328):900. PubMed ID: 9281070
    [No Abstract]   [Full Text] [Related]  

  • 9. Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist.
    Bristow LJ; Kramer MS; Kulagowski J; Patel S; Ragan CI; Seabrook GR
    Trends Pharmacol Sci; 1997 Jun; 18(6):186-8. PubMed ID: 9226994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of different monoamine receptors controlling MK-801-induced release of serotonin and glutamate in the medial prefrontal cortex: relevance for antipsychotic action.
    López-Gil X; Artigas F; Adell A
    Int J Neuropsychopharmacol; 2009 May; 12(4):487-99. PubMed ID: 18752722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.
    Krystal JH; D'Souza DC; Mathalon D; Perry E; Belger A; Hoffman R
    Psychopharmacology (Berl); 2003 Sep; 169(3-4):215-33. PubMed ID: 12955285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment.
    Snyder GL; Vanover KE
    Curr Pharm Des; 2014; 20(31):5093-103. PubMed ID: 24345266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PDE Inhibitors for the Treatment of Schizophrenia.
    Snyder GL; Vanover KE
    Adv Neurobiol; 2017; 17():385-409. PubMed ID: 28956340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia.
    Meltzer HY; Rajagopal L; Huang M; Oyamada Y; Kwon S; Horiguchi M
    Int J Neuropsychopharmacol; 2013 Nov; 16(10):2181-94. PubMed ID: 24099265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bridging pharmacology and neurodevelopment in schizophrenia.
    Kato T
    Int J Neuropsychopharmacol; 2007 Dec; 10(6):713-6. PubMed ID: 17651523
    [No Abstract]   [Full Text] [Related]  

  • 16. Clozapine treatment of schizophrenia.
    Pickar D; Hsiao JK
    JAMA; 1995 Sep; 274(12):981-3. PubMed ID: 7674530
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia.
    Singh AN; Barlas C; Saeedi H; Mishra RK
    J Psychiatry Neurosci; 2003 Jan; 28(1):39-47. PubMed ID: 12587849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia?
    Anghelescu IG; Janssens L; Kent J; de Boer P; Tritsmans L; Daly EJ; van Nueten L; Schmidt ME
    Eur Neuropsychopharmacol; 2013 Sep; 23(9):1043-50. PubMed ID: 22995972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations of dopamine and serotonin transmission in schizophrenia.
    Remington G
    Prog Brain Res; 2008; 172():117-40. PubMed ID: 18772030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
    Leucht S
    Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.